- Non-infectious recombinant 9-valent vaccine prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58
- Each 0.5-mL dose contains approximately:
- 30 mcg of HPV Type 6 L1 protein
- 40 mcg of HPV Type 11 L1 protein
- 60 mcg of HPV Type 16 L1 protein
- 40 mcg of HPV Type 18 L1 protein
- 20 mcg of HPV Type 31 L1 protein
- 20 mcg of HPV Type 33 L1 protein
- 20 mcg of HPV Type 45 L1 protein
- 20 mcg of HPV Type 52 L1 protein
- 20 mcg of HPV Type 58 L1 protein
- Administer GARDASIL 9 intramuscularly as a 0.5-mL dose at the following schedule:
- Initial
- 2 months
- 6 months
- Not all vulvar, vaginal, and anal cancers are caused by HPV, and GARDASIL 9 protects only against those vulvar, vaginal, and anal cancers caused by HPV 16, 18, 31, 33, 45, 52 and 5
- Prefilled Syringe
- Injection
- NDC Number: 00006-4121-02
- Requires Refrigeration
- 20 mcg - 60 mcg / 0.5 mL Strength
- Intramuscular
- For Females 9 to 26 Years of Age
- Males 9 through 15 Years of Age
